STRATA Skin Sciences to Participate in the Lytham Partners Spring 2022 Investor Conference

Rhea-AI Summary

STRATA Skin Sciences, Inc. (NASDAQ: SSKN) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The company's webcast presentation is scheduled for 11:00 AM ET on April 4 and will be accessible via their website. Management will also hold virtual one-on-one meetings throughout the event. STRATA specializes in medical technology for dermatology, offering products like the XTRAC and Pharos excimer lasers for various skin conditions, impacting over 31 million patients in the U.S.

HORSHAM, Pa., March 28, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced today that it will be participating in the Lytham Partners Spring 2022 Investor Conference taking place virtually on April 4-7, 2022.

The Company’s webcast presentation will be available for viewing at 11:00am ET on Monday, April 4, 2022, on the Company's website or at https://wsw.com/webcast/lytham4/sskn/2059581. The webcast will also be archived and available for replay.

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register at www.lythampartners.com/spring2022invreg.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear treatment system utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company’s proprietary XTRAC, XTRAC Momentum™ 1.0 and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. Additionally, STRATA’s recently acquired assets related to Theravant Corporation’s TheraClear system allows the company the expand into the U.S. acne care market.

STRATA’s unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact
Jack Droogan
(203) 585-4140
ir@strataskin.com

FAQ

When will STRATA Skin Sciences present at the Lytham Partners Spring 2022 Investor Conference?

STRATA Skin Sciences will present on April 4, 2022, at 11:00 AM ET.

How can I watch the STRATA Skin Sciences webcast presentation?

The webcast can be viewed on the STRATA Skin Sciences website.

What products does STRATA Skin Sciences offer for dermatologic conditions?

STRATA offers products like XTRAC, Pharos excimer lasers, and TheraClear for treating various skin conditions.

How many patients are impacted by conditions treated with STRATA's technology?

Over 31 million patients in the United States are impacted by conditions treatable with STRATA's technology.

What is STRATA Skin Sciences' strategy for increasing awareness of its products?

STRATA leverages targeted Direct to Consumer advertising and has in-house call centers for insurance advocacy.